According to GlobalData’s medical device pipeline database, 551 COVID-19 Point of Care (POC) Tests – Immuno Assay Tests devices are in various stages of development globally. GlobalData’s report provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 481 are in active development, while the remaining 93 are in an inactive stage of development. There are 174 products in the early stages of development, and the remaining 307 are in the late stages of development.
COVID-19 Immunoassay Tests are used to detect the antigens or antibodies specific to SARS-CoV-2 virus in the sample at the point-of-care (home or near-patient).
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed COVID-19 Point of Care (POC) Tests - Immuno Assay Tests pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of COVID-19 Point of Care (POC) Tests - Immuno Assay Tests devices. Overall, most of these COVID-19 Point of Care (POC) Tests - Immuno Assay Tests pipeline devices are being developed by private entities.
Key players involved in the active development of COVID-19 Point of Care (POC) Tests - Immuno Assay Tests include Abingdon Health, Aptamer Diagnostics, MedMira, LumiraDx, Guangzhou Wondfo Biotech, OraSure Technologies, Becton Dickinson and Co, Sorrento Therapeutics, Todos Medical and Trinity Biotech.
For a complete picture of the developmental pipeline for COVID-19 Point of Care (POC) Tests - Immuno Assay Tests devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
